Trial Details

COMPLETED
Basic Information
Clinical ID c865
Identifier NCT05913817
Trial Title The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.
Trial URL Visit Original Page
Study Information
Study Results

NO

Conditions Crohn Disease|Ulcerative Colitis|Rheumatoid Arthritis|Ankylosing Spondylitis|Psoriatic Arthritis|Plaque Psoriasis|Hidradenitis Suppurativa
Interventions BIOLOGICAL: AVT02 (Alvotech Biosimilar to Adalimumab)
Participant Information
Sponsor Jamp Pharma Corporation
City Quebec
Country/Region Canada
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT, OLDER_ADULT
Study Design
Study Type OBSERVATIONAL
Phase NULL
Time Information
Start Date 2023-01-09
Primary Completion Date 2025-07-31
Completion Date 2025-08-25